相关实验视频
Updated: Jun 6, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
110
早期阿尔茨海默病的液体生物标志物的现状和FDA监管的影响
Angelo M Jamerlan1, Seong Soo A An1, John P Hulme1
1Department of Bionanotechnology, Bionano Research Institute, Gachon University, 1342 Seongnam-daero, Sujeong-gu, Seongnam-si 13120, Gyeonggi-do, Republic of Korea.
Journal of the neurological sciences
|November 30, 2024
概括
本综述涵盖了早期阿尔茨海默病 (AD) 诊断的液体生物标志物,包括已知标志物如粉样蛋白β (Aβ) 和,以及新兴的标志物. 它还审查了FDA的情况.
科学领域:
- 神经学 神经学
- 生物化学 生物化学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 涉及到快速的皮层退化.
- 液体生物标志物,包括粉样β (Aβ) 和tau,对于AD诊断至关重要.
- 新型生物标志物显示有前途,但需要进一步验证.
研究的目的:
- 审查目前用于早期AD诊断的液体生物标志物的现状.
- 讨论这些生物标志物的潜力和局限性.
- 分析FDA的LDT法规对生物标志物开发的影响.
主要方法:
- 关于AD流体生物标志物的现有文献的叙述性综述.
- 对既有和新兴生物标志物的分析 (例如,Aβ,tau).
- 审查FDA对实验室开发的测试 (LDT) 的最终裁决.
主要成果:
- 像Aβ和tau这样的已知生物标志物是关键的,同位素的比例也很重要.
- 新兴的液体生物标志物显示出潜力,但需要更多的研究来确定可靠性.
- 美国食品和药物管理局对LDT作为医疗器械的监管将显著影响测试开发.
结论:
- 液体生物标志物正在为早期阿尔茨海默病检测取得进展,但验证仍在进行中.
- 由于FDA的行动,诊断测试的监管环境正在发展.
- 需要策略来指导开发人员通过对LDT的监管变化.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.粉样蛋白β是什么 粉样蛋白β是什么临床研究临床研究痴呆症是一种痴呆症.美国食品药品监督管理局 FDA FDA流体生物标志物 流体生物标志物LDTT 是一个LDT.在 NfL 中,它是NfL.有关监管的监管机构塔乌·塔乌 (Tau Tau) 是一个更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165